{"id":934573,"date":"2026-02-05T13:42:43","date_gmt":"2026-02-05T18:42:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/"},"modified":"2026-02-05T13:42:43","modified_gmt":"2026-02-05T18:42:43","slug":"microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/","title":{"rendered":"Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption"},"content":{"rendered":"<h2>\nParticipating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal Experiences<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">HINGHAM, Mass., Feb.  05, 2026  (GLOBE NEWSWIRE) &#8212; Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY<sup>\u00ae<\/sup> Endovascular Robotic System, announced that it is attending the Society of Interventional Oncology (SIO) annual meeting, being held in Savannah, GA, February 4-8, 2026. The timing of the conference, which is during the Company\u2019s limited market release of the LIBERTY System, will allow the Company to share practical insights and personal experiences from physicians who have used LIBERTY across hospitals and procedure types. This conference also marks the first commercial exhibition of LIBERTY following the commencement of the limited market release in late 2025, permitting the Company to directly engage with interventional oncologists with the goal of accelerating commercial awareness and adoption. Additionally, the Company will feature the LIBERTY System, offering hands-on live demonstrations of the robotic, single-use technology.<\/p>\n<p align=\"justify\">\u201cLIBERTY represents a new and differentiated robotic solution, targeting a large and expanding multi-billion dollar market, with interventional oncology serving as a key value driver in interventional radiology,\u201d commented Harel Gadot, CEO, President &amp; Chairman. \u201cInterventional oncology procedure volumes have increased significantly over the past decade, which we believe has created strong demand for advanced technologies such as LIBERTY. Engagement with interventional oncologists, including sharing user experience and reinforcing the breadth of LIBERTY\u2019s functionality, is expected to support the commercial traction of LIBERTY ahead of the full market release which is planned for April.\u201d<\/p>\n<p align=\"justify\">The Society of Interventional Oncology is a premier non-profit organization dedicated to establishing interventional oncology (IO) as the fourth pillar of cancer care alongside medical, surgical, and radiation oncology. SIO advances the field through evidence-based research, specialized education, and advocacy, providing a global community for practitioners.<\/p>\n<p align=\"justify\">LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY System in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.<\/p>\n<p align=\"justify\">\n        <strong>About Microbot Medical<\/strong>\n      <\/p>\n<p align=\"justify\">Microbot Medical Inc.\u00a0(NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot\u2019s LIBERTY<sup>\u00ae<\/sup> Endovascular Robotic System is the world\u2019s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.<\/p>\n<p align=\"justify\">Commercialization Robotics MedTech MBOT News Endovascular Robotics Medical Robotics Innovation SIO<\/p>\n<p>Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-OsVqkox_QltFeWUfVoW-m0qZMD6KgM32LbTtNi3Q7o7XvW51FrIKcUY4RuGoykZSgyd_NVB22dhFcwfRltNsSktJwB8Dc7qDpfSAwBTKG0=\" rel=\"nofollow\" target=\"_blank\">www.microbotmedical.com<\/a> and connect on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=15GNGdF06eHktldPY601jmAKLB3TSNpmXHKo99GA2rshUcAs5HaSkBljybFWwpQFo6Ax_VaHUD97xAcm9qsYudFwS4l7aY7BtOYi1Rc89rhuP1VkX-4cx9W7DwwJaeAl\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IrHYzlnFQDWbJZSjo-3guDgL9Z_EQgvC5cvgdBoGQf9wWan2QJMldVUuWOGuPp_8uBoVKcYmXeXro23sf6q7dw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">Statements to future financial and\/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as \u201ccontemplates,\u201d \u201ccontinues,\u201d \u201ccould,\u201d \u201cforecasts,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cestimates\u201d and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY<sup>\u00ae<\/sup> Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical<sup>\u00ae<\/sup> can be found under the heading \u201cRisk Factors\u201d in Microbot Medical\u2019s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC\u2019s web site at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8lTXnxii2UaLP9ENlAnkkFV-7dYXExsNe_HqwdNa_0Hs7CEin6d0ipHIC4GgdBWeloug1po0gl7qlktKeQEjlItdYBofjMZcG4Js8Yo5ZR-ZKiUEKizvx7HLJ0bvOKJmomSeL-4NWUn6djoRmbQupGl-6U0nePVCS-kUGidImhY=\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. Microbot Medical<sup>\u00ae<\/sup> disclaims any intent or obligation to update these forward-looking statements, except as required by law.<\/p>\n<p>\n        <strong>Contacts: <\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=puBiZNZWa4FHAlH6T7bCS2od8YpWyNibIrBqDOvXGoCnfDVVJSU5jkfPb0ZBzWuGi_ICHgrLZiFiQXA0aZQY7dnD6oHWECo5SMLSPWaqoyo=\" rel=\"nofollow\" target=\"_blank\">IR@microbotmedical.com<\/a><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4bcNhP1HFrXGvXrA8C43ma8whgShpIc00bYfD3cP5WpEPPTZ0ocwY7zkmMRxXYmzA6XoLP3rAQS2JUIj26m3o6t6gk0BWEzvLm7TYOVBo4P_H_t96Q3QyM5bXPoMlwlL\" rel=\"nofollow\" target=\"_blank\">Media@microbotmedical.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0OTU5MSM3NDExNDQxIzIwODI0OTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGIyZGEzMGYtMzllNi00ZGU4LTg4YjctY2MyYjc5MWYyODRhLTEwOTQwNjgtMjAyNi0wMi0wNS1lbg==\/tiny\/Microbot-Medical-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Participating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal Experiences HINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) &#8212; Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY\u00ae Endovascular Robotic System, announced that it is attending the Society of Interventional Oncology (SIO) annual meeting, being held in Savannah, GA, February 4-8, 2026. The timing of the conference, which is during the Company\u2019s limited market release of the LIBERTY System, will allow the Company to share practical insights and personal experiences from physicians who have used LIBERTY across hospitals and procedure types. This conference also marks the first commercial exhibition of LIBERTY following the commencement of the limited market release &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-934573","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Participating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal Experiences HINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) &#8212; Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY\u00ae Endovascular Robotic System, announced that it is attending the Society of Interventional Oncology (SIO) annual meeting, being held in Savannah, GA, February 4-8, 2026. The timing of the conference, which is during the Company\u2019s limited market release of the LIBERTY System, will allow the Company to share practical insights and personal experiences from physicians who have used LIBERTY across hospitals and procedure types. This conference also marks the first commercial exhibition of LIBERTY following the commencement of the limited market release &hellip; Continue reading &quot;Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-05T18:42:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0OTU5MSM3NDExNDQxIzIwODI0OTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption\",\"datePublished\":\"2026-02-05T18:42:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/\"},\"wordCount\":777,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0OTU5MSM3NDExNDQxIzIwODI0OTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/\",\"name\":\"Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0OTU5MSM3NDExNDQxIzIwODI0OTc=\",\"datePublished\":\"2026-02-05T18:42:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0OTU5MSM3NDExNDQxIzIwODI0OTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0OTU5MSM3NDExNDQxIzIwODI0OTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/","og_locale":"en_US","og_type":"article","og_title":"Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption - Market Newsdesk","og_description":"Participating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal Experiences HINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) &#8212; Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY\u00ae Endovascular Robotic System, announced that it is attending the Society of Interventional Oncology (SIO) annual meeting, being held in Savannah, GA, February 4-8, 2026. The timing of the conference, which is during the Company\u2019s limited market release of the LIBERTY System, will allow the Company to share practical insights and personal experiences from physicians who have used LIBERTY across hospitals and procedure types. This conference also marks the first commercial exhibition of LIBERTY following the commencement of the limited market release &hellip; Continue reading \"Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-05T18:42:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0OTU5MSM3NDExNDQxIzIwODI0OTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption","datePublished":"2026-02-05T18:42:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/"},"wordCount":777,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0OTU5MSM3NDExNDQxIzIwODI0OTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/","name":"Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0OTU5MSM3NDExNDQxIzIwODI0OTc=","datePublished":"2026-02-05T18:42:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0OTU5MSM3NDExNDQxIzIwODI0OTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0OTU5MSM3NDExNDQxIzIwODI0OTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/microbot-medical-to-leverage-current-users-experience-of-the-liberty-endovascular-robotic-system-at-key-oncology-conference-to-support-commercial-adoption\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Microbot Medical\u00ae to Leverage Current Users Experience of the LIBERTY\u00ae Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=934573"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934573\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=934573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=934573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=934573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}